Galectin Therapeutics Inc. - Warrants
GALTW
GALTW was delisted on the 23rd of March, 2017.
0 hedge funds and large institutions have $0 invested in Galectin Therapeutics Inc. - Warrants in 2017 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $42K → $0 (-$42K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$35K |
| 2 |
Neuberger Berman Group
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Millennium Management
New York
| – | -$35K | -640,800 | Closed |
|
|
2
Neuberger Berman Group
New York
| – | -$7K | -125,919 | Closed |
|
GALTW Hedge Fund Activity: Q1 2017 in Review
0 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics Inc. - Warrants (GALTW) for Q1 2017, worth a combined $0 — down 100% from $42K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GALTW and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Millennium Management, exiting entirely with an estimated $35K sold.
- 0 institutional investors held Galectin Therapeutics Inc. - Warrants (GALTW) as of Q1 2017, down from 4 in Q4 2016.
- Funds reported $0 of Galectin Therapeutics Inc. - Warrants stock for Q1 2017, down 100% quarter-over-quarter.
- 0 funds opened new Galectin Therapeutics Inc. - Warrants positions in Q1 2017 and 4 closed out, a net change of -4 holders.
- The largest Galectin Therapeutics Inc. - Warrants seller in Q1 2017 was Millennium Management, an estimated $35K sold.
Based on aggregated 13F filings for Q1 2017.